NCT04963738 is a Phase 1 clinical trial of JNJ-73763989 in Renal Impairment, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT04963738?

NCT04963738 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT04963738?

Interventions in NCT04963738: JNJ-73763989.

What condition does NCT04963738 study?

NCT04963738 studies Renal Impairment.

Is NCT04963738 still recruiting?

NCT04963738 is currently completed. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT04963738

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

Completed Phase 1 Last updated 9 November 2023

What this trial tests

Phase 1 trial testing JNJ-73763989 in Renal Impairment in 29 participants. Completed in 17 October 2022.

Timeline

22 September 2021

Primary endpoint
17 October 2022

17 October 2022

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	29
Start date	22 September 2021
Primary completion	17 October 2022
Estimated completion	17 October 2022
Sites	1 location across Germany

Drugs / interventions tested

JNJ-73763989 — full drug profile →

Conditions studied

Renal Impairment — all drugs for Renal Impairment →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

Adults 18 to 80, any sex, with Renal Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the pharmacokinetics (PK) of a single subcutaneous (SC) dose of JNJ-73763989 in adult participants with renal impairment compared with healthy participants with normal renal function.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor.
Ramírez-Cortés F, Ménová P. · · 2025 · cited 22× · PMID 39628900 · DOI 10.1039/d4md00652f
Recent Update on siRNA Therapeutics.
Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, et al · · 2025 · cited 19× · PMID 40331977 · DOI 10.3390/ijms26083456

Verify or expand the search:

Other trials of JNJ-73763989

Trials testing the same drug.

NCT05275023 — An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death P · Phase 2 · completed
NCT05123599 — A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBe · Phase 1 · completed
NCT05005507 — A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis · Phase 2 · terminated
NCT04585789 — A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus · Phase 2 · completed
NCT04667104 — A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppres · Phase 2 · completed

Other recruiting trials for Renal Impairment

Currently open trials in the same condition.

NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
NCT07315360 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function · Phase 1 · recruiting
NCT07217886 — A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls · Phase 1 · recruiting
NCT07154901 — Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD23 · Phase 1 · recruiting
NCT07017933 — Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes · NA · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04963738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04963738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing